Introduction
============

Dabigatran is a new oral anticoagulant drug used widely for the prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation [@B1]. The Food and Drug Administration (FDA) approved dabigatran based on the results the phase III, prospective, randomized, open-label multi-national Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) clinical trial [@B2]. In the RE-LY trial, the rate of stroke and systemic embolism was similar between dabigatran and warfarin [@B2]. Major bleeding was significantly reduced with dabigatran (110 mg), as compared to warfarin, whereas 150 mg showed an effect similar to warfarin. Furthermore, dabigatran was associated with lower rates of major bleeding and intracranial bleeding than warfarin treatment [@B2].

Dabigatran is primarily excreted unmetabolized by the kidneys [@B3]. It was reported that dabigatran concentrations increase approximately two- to three-fold in patients with moderate renal impairment, as compared to patients with normal renal function [@B4]. Indeed, gastrointestinal (GI) bleeding was increased with 150 mg dabigatran, but not 110 mg dabigatran [@B2]. Thus, higher blood concentrations of dabigatran may increase the risk of GI bleeding [@B5].

The effects of dabigatran on GI bleeding are of interest in older patients, because atrial fibrillation is largely a disease of the elderly, and the risk of stroke and bleeding increases with advanced age. In the RE-LY trial, Eikelboom *et al.* reported that, in patients older than 75, the risk of intracranial bleeding was lower, but the risk of extra-cranial bleeding was similar or higher with both doses (150 mg and 110 mg) of dabigatran, as compared to warfarin [@B5]. Because ischemic strokes and systemic embolisms have greater clinical significance than nonfatal bleeding, such as GI bleeding, higher doses of dabigatran are more favorable in elderly patients [@B2]. However, acute and chronic GI bleeding has a negative effect on a patient\'s quality of life.

The FDA Adverse Event Reporting System (FAERS) database, a spontaneous reporting system, is the primary tool used for pharmacovigilance. The FAERS is a rich resource, and data mining indices provide a powerful means to identify potential associations between drugs and adverse events. Dabigatran is a direct oral thrombin inhibitor, and is administered in a fixed dose, without laboratory monitoring [@B6]. Initially, it was expected to be an alternative therapy to warfarin; however, reports of serious and fatal bleeding events associated with dabigatran use increased in the FAERS database after approval [@B7]. Thus, the effects of dabigatran use on internal bleeding remain unclear. In the RE-LY study, patients with severe renal impairment were excluded [@B2], [@B6]. In contrast, the FAERS database contains information on patients with varying renal function, ranging from normal to severe dysfunction. Thus, evaluation of GI bleeding events using the FAERS database is valuable, because it reflects the realities of clinical practice.

Recently, data mining algorithms have been developed for use in spontaneous adverse event reporting databases, such as the FAERS database, to identify drug-associated adverse events by disproportionality analysis [@B8], [@B9]. The crude reporting odds ratio (ROR) is used by the Pharmaceuticals and Medical Devices Agency in Japan and the Netherlands Pharmacovigilance Center [@B10]. The crude ROR is an applicable technique that allows for adjustments through logistic regression analyses and control of covariates [@B11]. We hypothesized that it may be possible to adjust for the above-mentioned reporting bias using this approach.

The effects of aging on dabigatran- and warfarin-induced bleeding have not yet assessed using RORs adjusted by logistic regression analyses. The purpose of this study was to evaluate the relationship between aging and dabigatran-associated hemorrhage, and to compare the data with that obtained from warfarin using the FAERS database.

Methods
=======

Data sources
------------

The FAERS database, which covered the period from January 2004 to March 2014, was obtained from the FDA website ([www.fda.gov](http://www.fda.gov)). The FAERS structure complies with the international safety reporting guidelines, ICH E2B. The adverse events are coded according to the terminology preferred by the Medical Dictionary for Regulatory Activities (MedDRA) [@B12].

The drugs selected for this investigation were dabigatran and warfarin. The FAERS database permits contributors to register drugs under any name, including a trade name and an abbreviation. The DrugBank database contains drug information used globally, including 1,447 FDA-approved small molecule drugs [@B13], and was utilized as a dictionary for the batch conversion and compilation of drug names. For duplicate entries, we followed the FDA\'s recommendation as described on the FAERS website, to adopt the most recent case number to identify duplicate reports from the same patient and excluded them from the analysis.

Definition of hemorrhage events
-------------------------------

This study relied on definitions provided by MedDRA version 17.1. To evaluate dabigatran- and warfarin-associated hemorrhagic events in the GI system, we utilized the Standardized MedDRA Query (SMQ) for *hemorrhages events*(SMQ code: 20000038) and the System Organ Class (SOC) for *gastrointestinal disorder*, and selectively extracted reports that met both criteria. The number of selected preferred terms for *hemorrhages*, limited by the SOC (*gastrointestinal disorder*), was 71. Furthermore, to evaluate dabigatran- and warfarin-associated hemorrhagic events in the nervous system, such as intracranial hemorrhage, we utilized 35 preferred terms that matched the SMQ for *hemorrhages events*(SMQ code: 20000038) and the SOC (*nervous system disorder*).

Analysis
--------

Using established pharmacovigilance indices, we evaluated the reporting odds ratio (ROR) to establish the effects of dabigatran and warfarin on "hemorrhagic events." "Cases" were defined as patients who reported "hemorrhagic events," while "non-cases" consisted of patients associated with all other reports. The reporting odds ratio (ROR) is the ratio of the odds of reporting adverse events versus all other events associated with dabigatran or warfarin compared to the reporting odds for all other drugs present in the database. To compare the "cases" and "non-cases," we calculated the RORs as (a:c)/(b:d). RORs were expressed as point estimates with a 95% confidence interval (CI). To evaluate the effect of age on "hemorrhagic events," the reports were stratified into age groups: 0-29, 30-39, 40-49, 50-59, 60-69, 70-79, 80-89, and greater than 90.

For signal detection, general qualitative judgments were used. The detection of a signal was dependent on the signal indices exceeding a predefined threshold. ROR values \< 1 indicated no exposure-event association, and estimates \> 1 indicated exposure-event safety signals. Safety signals are considered significant when the ROR estimates and the lower limits of the corresponding 95% CI are ≥ 2. [@B10]

We refined the signal with a dedicated correction to detect possible confounders present in the database using logistic regression analysis. After adjusting for gender, reporting year, and stratified age groups, the RORs were calculated using logistic regression analysis. To construct the logistic model, the drugs and stratified age groups were coded. The following logistic model was used for analysis:
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(G = gender, Y = reporting year, D = drug (dabigatran or warfarin), and A = stratified age group)

The adjusted RORs were calculated using the 40-49 year old group as a reference group. This model can be compared with a model in which no interaction term is present. A likelihood ratio test can be used to evaluate the effect of adding this term. Because the difference in -2 log likelihood follows a chi-square distribution with one degree of freedom after adding the interaction term, a probability (*p*) value of 0.05 or less was considered statistically significant. Data analyses were performed using JMP, version 11.0 (SAS Institute Inc., Cary, NC, USA).

Results
=======

The FAERS database contains 5,597,297 reports from the first quarter of 2004 through the end of the first quarter of 2014. After excluding duplicates according to the FDA recommendation and extracting reports that contained the age and the gender of the patients, 2,143,443 reports were analyzed. The RORs of dabigatran and warfarin are summarized in Table [2](#T2){ref-type="table"}. The RORs (95% CI) of hemorrhage associated with dabigatran, limited by the SOC (GI disorders), in patients age 40-49, 70-79, 80-89, and ≥ 90 were 4.88 (3.26-7.31), 13.55 (12.79-14.35), 19.34 (18.30-20.44), and 26.18 (23.05-29.74), respectively. The RORs for gastrointestinal hemorrhage increased with advancing age after dabigatran treatment (Figure [1](#F1){ref-type="fig"}). The RORs (95% CI) of hemorrhage associated with warfarin, limited by the SOC (GI disorders), in patients age 40-49, 70-79, 80-89, and ≥ 90 were 2.95 (2.55-3.41), 4.74 (4.46-5.03), 5.80 (5.42-6.20), and 5.39 (4.42-6.57), respectively. The ROR signal for GI hemorrhage in elderly patients treated with dabigatran was higher than in patients treated with warfarin.

The RORs (95% CI) of hemorrhage associated with dabigatran, limited by the SOC (nervous system disorders), in patients age 40-49, 70-79, 80-89, and ≥ 90 were 3.54 (1.46-8.57), 9.57 (8.54-10.72), 10.44 (9.31-11.71), and 10.11 (7.63-13.40), respectively (Table [3](#T3){ref-type="table"}). The RORs (95% CI) of hemorrhage associated with warfarin, limited by the SOC (nervous system disorders), in patients age 40-49, 70-79, 80-89, and ≥ 90 were 2.79 (2.09-3.72), 4.92 (4.40-5.50), 6.58 (5.85-7.41), and 6.14 (4.34-8.69), respectively. The RORs for nervous system hemorrhage had no significant correlation with age.

The number of GI hemorrhage cases and crude RORs (95% CI) are summarized in Table [4](#T4){ref-type="table"}. The crude RORs (95% CI) for GI hemorrhage in dabigatran-treated patients aged 80-89 and ≥ 90 were 10.61 (9.98-11.28) and 13.22 (11.42-15.30), respectively. The likelihood ratio test of the interaction terms dabigatran\*60-69, dabigatran\*80-89 and dabigatran\*≥ 90 were statistically significant (Table [6](#T6){ref-type="table"}). The adjusted RORs for dabigatran\*60-69, dabigatran\*80-89, and dabigatran\*≥ 90, were 16.66 (95% CI, 11.01-25.23), 31.36 (95% CI, 20.81-47.26), and 45.14 (95% CI, 29.30-69.53), respectively. In contrast, the crude RORs (95% CI) for warfarin did not increase with advancing age (Table [5](#T5){ref-type="table"}). The likelihood ratio test of the interaction term warfarin\*70-79, warfarin\*80-89, and warfarin\*≥ 90 were statistically significant (Table [6](#T6){ref-type="table"}). The adjusted RORs for warfarin\*70-79, warfarin\*80-89, and warfarin\*≥ 90, were 7.33 (95% CI, 6.23-8.62), 9.21 (95% CI, 7.80-10.87), and 9.02 (95% CI, 6.96-11.69).

The crude ROR for dabigatran- and warfarin-associated nervous system hemorrhage did not increase with advancing age. Further, the likelihood ratio test of the interaction term was not statistically significant (Table [6](#T6){ref-type="table"}).

Discussion
==========

Bleeding is the most common complication associated with the use of anticoagulant drugs. We examined the association between hemorrhagic events in the GI and nervous system and anticoagulant drugs (dabigatran and warfarin) after stratification by age. In this study, we demonstrated that dabigatran-associated GI hemorrhage was significantly increased in patients over the age of 80 (Table [6](#T6){ref-type="table"}). Evaluation of GI hemorrhage revealed that the adjusted RORs of dabigatran increased with advancing age, whereas aging had little effect on warfarin (Table [6](#T6){ref-type="table"} and Figure [1](#F1){ref-type="fig"}). The adjusted ROR for dabigatran-associated GI hemorrhage was higher than the adjusted ROR of warfarin. Our study supports the results of the RE-LY trials and the safety announcements issued by regulating authorities. In contrast, the RORs of dabigatran- and warfarin-associated nervous system hemorrhage were less affected by aging (Figure [2](#F2){ref-type="fig"}, Table [6](#T6){ref-type="table"}). Since dabigatran is primarily excreted by the kidney and warfarin is metabolized in the liver by cytochrome P450 [@B14], the effect of dabigatran on GI hemorrhage may be affected by changes in kidney function due to aging.

The RE-LY trial indicated that dabigatran is associated with a reduced risk of intracranial hemorrhage, as compared to warfarin [@B5]. Furthermore, new retrospective post-marketing studies also indicate that dabigatran is associated with a lower risk of intracranial hemorrhage [@B15], [@B16]. In contrast, the adjusted dabigatran RORs for nervous system hemorrhage did not indicate lower adjusted RORs compared to warfarin in our study (dabigatran: 5.61 \[95% CI 1.99-12.22\]; warfarin: 4.83 \[95% CI 3.55-6.41\]) (Table [6](#T6){ref-type="table"}). Our results showd that the 95% CI of the adjusted dabigatran RORs was broad and not significant. We do not have a conclusive explanation for these data. We adjusted the crude ROR by coding the terms of gender, reporting year, drug, and stratified age groups in the logistic mode. However, our results from the FAERS database using this logistic model could not account for our observations. This contradiction could be considered the result of unobserved bias. Alternatively, differences in the definition of hemorrhagic adverse events in our study, the Preferred Terms (PTs) from MedDRA, and other studies could cause this effect. Furthermore, the manufacturer recommends that high-risk elderly patients (over 75 years of age) and those with chronic kidney disease should be given a lower dose of dabigatran; however, we could not determine whether dabigatran doses were lowered.

The pharmacokinetic profile of dabigatran can be affected by concomitant administration of several drugs. Dabigatran etexilate is a substrate for p-glycoprotein; thus, drugs that inhibit or induce p-glycoprotein could potentiate or attenuate the anticoagulant effect of dabigatran [@B3]. The effects of this drug-drug interaction should be evaluated with respect to anticoagulant-associated hemorrhage using a well-organized epidemiologic studies and/or the FAERS database.

After the approval of dabigatran, the FDA received numerous reports of severe dabigatran-related bleeding events [@B7]. Safety advisories have been issued by the FDA, the European Medicine Agency, and the Australian Therapeutic Goods Authority [@B17]-[@B19]. The reports of increased bleeding with dabigatran differed from those in the RE-LY trial, and were likely the result of passive reporting in the FAERS database, which can lead to reporting bias. Currently, the increase in severe bleeding events associated with dabigatran in the FAERS database is regarded as the result of reporting bias [@B7]. Thus, regulating authorities have not altered the safety profile of dabigatran, based on its overall benefit-risk profile [@B17], [@B20].

Several post-marketing studies provide more data on the bleeding risks among patients with atrial fibrillation [@B15], [@B16]. A large post-marketing study of dabigatran evaluating 134,414 elderly patients showed the comparative safety of dabigatran versus warfarin in general practice settings between October 2010 and December 2012 [@B16]. This analysis confirmed a reduced risk of major bleeding and intracranial hemorrhage with dabigatran. In a press release, Boehringer Ingelheim, Inc. pointed out that the FDA analysis supported the positive safety and efficacy profile of dabigatran in the RE-LY trial [@B21].

Another retrospective post-marketing study evaluating 9,404 Medicare patients over a 6-month follow-up period reported that dabigatran was associated with a higher incidence of major bleeding relative to warfarin, a higher risk of gastrointestinal bleeding, but a lower risk of intracranial hemorrhage [@B15]. Their results differed from the RE-LY trial, which showed no difference in the rates of major bleeding with dabigatran and warfarin. The risk of major bleeding among dabigatran users was especially high for African Americans and patients with chronic kidney disease. These results should be interpreted with caution, due to the relatively small size of the study.

Disproportionality analysis has several limitations that are inherent to the nature of the data and require consideration prior to drawing conclusions. In general, ROR cannot be used to infer the comparative strength of causality [@B22], [@B23]. Rather, it offers a rough indication of the signal strength, used to generate hypotheses to search for unknown potential adverse reactions [@B24]. It is impossible to evaluate the "true" risk of hemorrhage without information concerning the total number of patients administered dabigatran. Since dabigatran and warfarin users are very different in several factors that directly affect the risk of bleeding, failing to adjust would bias the results, as our unadjusted estimates indicate. While hemorrhagic events have been document in the FAERS database, careful attention must be paid to the interpretation of the results.

Recently, the use of quantitative measures, in addition to qualitative analysis, has become increasingly important in signal detection for pharmacovigilance [@B22]. Several researchers have demonstrated that disproportionality measures can provide new, causal insights. These studies each use an approach that might circumvent biases, such as selection and reporting biases. Mitigating the effect of confounding factors by such approaches enhances the robustness of results. For example, van Puijenbroek *et al.* evaluated the association between two drugs and a single event (drug-drug interactions) using a statistical interaction term in a logistic model to calculate the adjusted RORs [@B11].

To our knowledge, reports on safety signal detection using logistic regression analyses focusing on age stratification are scarce. This study was the first to evaluate the association between aging and dabigatran and warfarin in GI and nervous system bleeding using the FAERS database by logistic regression. We adjusted the crude ROR by coding the terms of gender, reporting year, drug, and stratified age groups in the logistic model. In our logistic regression analysis, the adjusted RORs after adding adjusting terms were different than the crude RORs (Table [6](#T6){ref-type="table"}). Thus, the adjustment of variables might influence the reporting ratio of adverse events. We demonstrated that the effect of age on the association between dabigatran and GI bleeding cannot be ignored in spontaneous adverse reporting. We consider our results valid, due to the appropriate analysis methods and the special attention paid to potential bias.

Until more evidence is available, prescribers should carefully monitor bleeding complications in elderly patients with renal impairment, a group that is known to have an increased risk of bleeding. This information could potentially be useful for improved management of GI bleeding during dabigatran treatment, and may be particularly beneficial to prescribers.

We sought to evaluate, using a real-world setting, any differences in bleeding between dabigatran users after adjusting for patient differences using appropriate analysis methods. Our study indicates the importance of comparing the safety profiles of newer and traditional drugs using post-marketing real-world data. After considering the causality in the current analysis, further epidemiological studies are recommended in elderly patients.

This research was partially supported by JSPS KAKENHI Grant Number, 24390126.
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###### 

Characteristics of cases and non-cases, hemorrhage events (SMQ20000038) limited by SOC for gastrointestinal disorder and nervous system disorder

                                              Case     (   \%     )   Non-Case    (   \%     )   Total       Reporting Odds Ratio (95%CI)                            
  ----------------------------- ------------- -------- --- ------ --- ----------- --- ------ --- -------- -- ------------------------------ --- ------- ---- ------- ---
  *Gastrointestinal disorder*                                                                                                                                        
                                Total         43,758                  2,099,685                                                                                      
                                Gender Male   21325    (   48.7   )   795968      (   37.9   )   817293      1.56                           (   1.53    \-   1.59    )
                                Dabigatran    4541     (   10.4   )   15186       (   0.7    )   19727       15.89                          (   15.41   \-   16.45   )
                                Warfarin      4035     (   9.2    )   43596       (   2.1    )   47631       4.73                           (   4.64    \-   4.95    )
                                Mean age      60.8                    53                                                                                             
  *Nervous system disorder*                                                                                                                                          
                                Total         10,868                  2,132,575                                                                                      
                                Gender Male   5479     (   50.4   )   811814      (   38.1   )   817293      1.65                           (   1.59    \-   1.71    )
                                Dabigatran    888      (   8.2    )   18839       (   0.9    )   19727       9.98                           (   9.30    \-   10.70   )
                                Warfarin      1098     (   10.1   )   46535       (   2.2    )   47631       5.04                           (   4.73    \-   5.37    )
                                Mean age      61.7                    53.1                                                                                           

###### 

Characteristics of cases and non-cases, dabigatran or warfarin associated with hemorrhage events (SMQ20000038) limited by SOC for gastrointestinal disorder

  Drug name   Age            Total                       Cases   Non-cases   Rate   Reporting odds Ratio                                            
  ----------- -------------- --------------------------- ------- ----------- ------ ---------------------- ------- ------- --- ------- ---- ------- ---
              *Dabigatran*                                                                                                                          
                             Reference                                                                                                              
                                                         0-29    291711      4274   287437                 9.77    0.76    (   0.74    \-   0.78    )
                                                         30-39   216892      2525   214367                 5.77    0.60    (   0.58    \-   0.62    )
                                                         40-49   313483      3980   309503                 9.10    0.65    (   0.63    \-   0.67    )
                                                         50-59   437570      6594   430976                 15.07   0.78    (   0.76    \-   0.80    )
                                                         60-69   418434      8319   410115                 19.01   1.10    (   1.07    \-   1.13    )
                                                         70-79   286535      7844   278691                 17.93   1.62    (   1.58    \-   1.66    )
                                                         80-89   139953      4928   135025                 11.26   2.07    (   2.01    \-   2.13    )
                                                         ≥ 90    19138       753    18385                  1.72    2.20    (   2.04    \-   2.37    )
                             Dabigatran administration                                                                                              
                                                         0-29    104         24     80                     0.05    14.40   (   9.12    \-   22.73   )
                                                         30-39   76          8      68                     0.02    5.65    (   2.72    \-   11.76   )
                                                         40-49   282         26     256                    0.06    4.88    (   3.26    \-   7.31    )
                                                         50-59   1148        167    981                    0.38    8.20    (   6.96    \-   9.66    )
                                                         60-69   3620        649    2971                   1.48    10.62   (   9.75    \-   11.57   )
                                                         70-79   7059        1515   5544                   3.46    13.55   (   12.79   \-   14.35   )
                                                         80-89   6393        1785   4608                   4.08    19.34   (   18.30   \-   20.44   )
                                                         ≥ 90    1045        367    678                    0.84    26.18   (   23.05   \-   29.74   )
              *Warfarin*                                                                                                                            
                             Reference                                                                                                              
                                                         0-29    290568      4243   286325                 9.70    0.74    (   0.72    \-   0.76    )
                                                         30-39   215267      2450   212817                 5.60    0.57    (   0.55    \-   0.59    )
                                                         40-49   310402      3812   306590                 8.71    0.61    (   0.59    \-   0.63    )
                                                         50-59   432272      6324   425948                 14.45   0.72    (   0.70    \-   0.74    )
                                                         60-69   411028      7981   403047                 18.24   1.03    (   1.00    \-   1.06    )
                                                         70-79   280036      8165   271871                 18.66   1.70    (   1.66    \-   1.74    )
                                                         80-89   137147      5738   131409                 13.11   2.47    (   2.40    \-   2.54    )
                                                         ≥ 90    19092       1010   18082                  2.31    2.94    (   2.76    \-   3.13    )
                             Warfarin administration                                                                                                
                                                         0-29    1247        55     1192                   0.13    2.22    (   1.69    \-   2.91    )
                                                         30-39   1701        83     1618                   0.19    2.46    (   1.97    \-   3.07    )
                                                         40-49   3363        194    3169                   0.44    2.95    (   2.55    \-   3.41    )
                                                         50-59   6446        437    6009                   1.00    3.51    (   3.18    \-   3.87    )
                                                         60-69   11026       987    10039                  2.26    4.80    (   4.49    \-   5.13    )
                                                         70-79   13558       1194   12364                  2.73    4.74    (   4.46    \-   5.03    )
                                                         80-89   9199        975    8224                   2.23    5.80    (   5.42    \-   6.20    )
                                                         ≥ 90    1091        110    981                    0.25    5.39    (   4.42    \-   6.57    )

###### 

Characteristics of cases and non-cases, dabigatran or warfarin associated hemorrhage events (SMQ20000038) limited by SOC for nervous system disorder

  Drug name   Age            Total                       Cases   Non-cases   Rate   Reporting odds Ratio                                           
  ----------- -------------- --------------------------- ------- ----------- ------ ---------------------- ------- ------- --- ------ ---- ------- ---
              *Dabigatran*                                                                                                                         
                             Reference                                                                                                             
                                                         0-29    291711      904    290807                 8.32    0.62    (   0.58   \-   0.66    )
                                                         30-39   216892      562    216330                 5.17    0.52    (   0.48   \-   0.57    )
                                                         40-49   313483      938    312545                 8.63    0.60    (   0.56   \-   0.64    )
                                                         50-59   437570      1587   435983                 14.60   0.73    (   0.69   \-   0.77    )
                                                         60-69   418434      2180   416254                 20.06   1.14    (   1.09   \-   1.20    )
                                                         70-79   286535      2164   284371                 19.91   1.78    (   1.70   \-   1.87    )
                                                         80-89   139953      1469   138484                 13.52   2.46    (   2.33   \-   2.60    )
                                                         ≥ 90    19138       176    18962                  1.62    1.98    (   1.70   \-   2.30    )
                             Dabigatran administration                                                                                             
                                                         0-29    104         5      99                     0.05    9.91    (   4.03   \-   24.34   )
                                                         30-39   76          4      72                     0.04    10.91   (   3.99   \-   29.87   )
                                                         40-49   282         5      277                    0.05    3.54    (   1.46   \-   8.57    )
                                                         50-59   1148        44     1104                   0.40    7.85    (   5.80   \-   10.62   )
                                                         60-69   3620        144    3476                   1.32    8.22    (   6.95   \-   9.72    )
                                                         70-79   7059        320    6739                   2.94    9.57    (   8.54   \-   10.72   )
                                                         80-89   6393        315    6078                   2.90    10.44   (   9.31   \-   11.71   )
                                                         ≥ 90    1045        51     994                    0.47    10.11   (   7.63   \-   13.40   )
              *Warfarin*                                                                                                                           
                             Reference                                                                                                             
                                                         0-29    290568      887    289681                 8.16    0.62    (   0.58   \-   0.66    )
                                                         30-39   215267      541    214726                 4.98    0.51    (   0.47   \-   0.56    )
                                                         40-49   310402      896    309506                 8.24    0.58    (   0.54   \-   0.62    )
                                                         50-59   432272      1495   430777                 13.76   0.69    (   0.65   \-   0.73    )
                                                         60-69   411028      2105   408923                 19.37   1.13    (   1.08   \-   1.19    )
                                                         70-79   280036      2160   277876                 19.87   1.85    (   1.76   \-   1.94    )
                                                         80-89   137147      1492   135655                 13.73   2.59    (   2.45   \-   2.74    )
                                                         ≥ 90    19092       194    18898                  1.79    2.22    (   1.92   \-   2.56    )
                             Warfarin administration                                                                                               
                                                         0-29    1247        22     1225                   0.20    3.53    (   2.31   \-   5.38    )
                                                         30-39   1701        25     1676                   0.23    2.93    (   1.97   \-   4.35    )
                                                         40-49   3363        47     3316                   0.43    2.79    (   2.09   \-   3.72    )
                                                         50-59   6446        136    6310                   1.25    4.27    (   3.60   \-   5.07    )
                                                         60-69   11026       219    10807                  2.02    4.04    (   3.53   \-   4.62    )
                                                         70-79   13558       324    13234                  2.98    4.92    (   4.40   \-   5.50    )
                                                         80-89   9199        292    8907                   2.69    6.58    (   5.85   \-   7.41    )
                                                         ≥ 90    1091        33     1058                   0.30    6.14    (   4.34   \-   8.69    )

###### 

Stratified analysis of gastrointestinal hemorrhage

                                             Cases   Non-cases   Total       Crude ROR (95% CI)                            
  ------------------ -------------- -------- ------- ----------- -------- -- -------------------- --- ------- ---- ------- ---
  ***Dabigatran***                                                                                                         
                     *0-29 y.o.*    Drug -   4274    287437      291711                                                    
                                    Drug +   24      80          104         20.18                (   12.78   \-   31.88   )
                                    Total    4298    287517      291815                                                    
                                                                                                                           
                     *30-39 y.o.*   Drug -   2525    214367      216892                                                    
                                    Drug +   8       68          76          9.99                 (   4.80    \-   20.81   )
                                    Total    2533    214435      216968                                                    
                                                                                                                           
                     *40-49 y.o.*   Drug -   3980    309503      313483                                                    
                                    Drug +   26      256         282         7.90                 (   5.27    \-   11.84   )
                                    Total    4006    309759      313765                                                    
                                                                                                                           
                     *50-59 y.o.*   Drug -   6594    430976      437570                                                    
                                    Drug +   167     981         1148        11.13                (   9.43    \-   13.14   )
                                    Total    6761    431957      438718                                                    
                                                                                                                           
                     *60-69 y.o.*   Drug -   8319    410115      418434                                                    
                                    Drug +   649     2971        3620        10.77                (   9.87    \-   11.76   )
                                    Total    8968    413086      422054                                                    
                                                                                                                           
                     *70-79 y.o.*   Drug -   7844    278691      286535                                                    
                                    Drug +   1515    5544        7059        9.71                 (   9.13    \-   10.32   )
                                    Total    9359    284235      293594                                                    
                                                                                                                           
                     *80-89 y.o.*   Drug -   4928    135025      139953                                                    
                                    Drug +   1785    4608        6393        10.61                (   9.98    \-   11.28   )
                                    Total    6713    139633      146346                                                    
                                                                                                                           
                     *≥ 90 y.o.*    Drug -   753     18385       19138                                                     
                                    Drug +   367     678         1045        13.22                (   11.42   \-   15.30   )
                                    Total    1120    19063       20183                                                     
  ***Warfarin***                                                                                                           
                     *0-29 y.o.*    Drug -   4243    286325      290568                                                    
                                    Drug +   55      1192        1247        3.11                 (   2.37    \-   4.08    )
                                    Total    4298    287517      291815                                                    
                                                                                                                           
                     *30-39 y.o.*   Drug -   2450    212817      215267                                                    
                                    Drug +   83      1618        1701        4.46                 (   3.56    \-   5.58    )
                                    Total    2533    214435      216968                                                    
                                                                                                                           
                     *40-49 y.o.*   Drug -   3812    306590      310402                                                    
                                    Drug +   194     3169        3363        4.92                 (   4.24    \-   5.71    )
                                    Total    4006    309759      313765                                                    
                                                                                                                           
                     *50-59 y.o.*   Drug -   6324    425948      432272                                                    
                                    Drug +   437     6009        6446        4.90                 (   4.43    \-   5.42    )
                                    Total    6761    431957      438718                                                    
                                                                                                                           
                     *60-69 y.o.*   Drug -   7981    403047      411028                                                    
                                    Drug +   987     10039       11026       4.97                 (   4.64    \-   5.33    )
                                    Total    8968    413086      422054                                                    
                                                                                                                           
                     *70-79 y.o.*   Drug -   8165    271871      280036                                                    
                                    Drug +   1194    12364       13558       3.22                 (   3.02    \-   3.43    )
                                    Total    9359    284235      293594                                                    
                                                                                                                           
                     *80-89 y.o.*   Drug -   5738    131409      137147                                                    
                                    Drug +   975     8224        9199        2.72                 (   2.53    \-   2.92    )
                                    Total    6713    139633      146346                                                    
                                                                                                                           
                     *≥ 90 y.o.*    Drug -   1010    18082       19092                                                     
                                    Drug +   110     981         1091        2.01                 (   1.63    \-   2.47    )
                                    Total    1120    19063       20183                                                     

###### 

Stratified analysis of nervous system hemorrhage

                                             Cases   Non-cases   Total       Crude ROR (95% CI)                           
  ------------------ -------------- -------- ------- ----------- -------- -- -------------------- --- ------ ---- ------- ---
  ***Dabigatran***                                                                                                        
                     *0-29 y.o.*    Drug -   904     290807      291711                                                   
                                    Drug +   5       99          104         16.25                (   6.60   \-   40.00   )
                                    Total    909     290906      291815                                                   
                                                                                                                          
                     *30-39 y.o.*   Drug -   562     216330      216892                                                   
                                    Drug +   4       72          76          21.38                (   7.79   \-   58.72   )
                                    Total    566     216402      216968                                                   
                                                                                                                          
                     *40-49 y.o.*   Drug -   938     312545      313483                                                   
                                    Drug +   5       277         282         6.01                 (   2.48   \-   14.59   )
                                    Total    943     312822      313765                                                   
                                                                                                                          
                     *50-59 y.o.*   Drug -   1587    435983      437570                                                   
                                    Drug +   44      1104        1148        10.95                (   8.07   \-   14.86   )
                                    Total    1631    437087      438718                                                   
                                                                                                                          
                     *60-69 y.o.*   Drug -   2180    416254      418434                                                   
                                    Drug +   144     3476        3620        7.91                 (   6.66   \-   9.39    )
                                    Total    2324    419730      422054                                                   
                                                                                                                          
                     *70-79 y.o.*   Drug -   2164    284371      286535                                                   
                                    Drug +   320     6739        7059        6.24                 (   5.54   \-   7.03    )
                                    Total    2484    291110      293594                                                   
                                                                                                                          
                     *80-89 y.o.*   Drug -   1469    138484      139953                                                   
                                    Drug +   315     6078        6393        4.89                 (   4.32   \-   5.54    )
                                    Total    1784    144562      146346                                                   
                                                                                                                          
                     *≥ 90 y.o.*    Drug -   176     18962       19138                                                    
                                    Drug +   51      994         1045        5.53                 (   4.02   \-   7.60    )
                                    Total    227     19956       20183                                                    
  ***Warfarin***                                                                                                          
                     *0-29 y.o.*    Drug -   887     289681      290568                                                   
                                    Drug +   22      1225        1247        5.87                 (   3.83   \-   8.99    )
                                    Total    909     290906      291815                                                   
                                                                                                                          
                     *30-39 y.o.*   Drug -   541     214726      215267                                                   
                                    Drug +   25      1676        1701        5.92                 (   3.95   \-   8.87    )
                                    Total    566     216402      216968                                                   
                                                                                                                          
                     *40-49 y.o.*   Drug -   896     309506      310402                                                   
                                    Drug +   47      3316        3363        4.90                 (   3.65   \-   6.58    )
                                    Total    943     312822      313765                                                   
                                                                                                                          
                     *50-59 y.o.*   Drug -   1495    430777      432272                                                   
                                    Drug +   136     6310        6446        6.21                 (   5.20   \-   7.41    )
                                    Total    1631    437087      438718                                                   
                                                                                                                          
                     *60-69 y.o.*   Drug -   2105    408923      411028                                                   
                                    Drug +   219     10807       11026       3.94                 (   3.42   \-   4.53    )
                                    Total    2324    419730      422054                                                   
                                                                                                                          
                     *70-79 y.o.*   Drug -   2160    277876      280036                                                   
                                    Drug +   324     13234       13558       3.15                 (   2.80   \-   3.54    )
                                    Total    2484    291110      293594                                                   
                                                                                                                          
                     *80-89 y.o.*   Drug -   1492    135655      137147                                                   
                                    Drug +   292     8907        9199        2.98                 (   2.62   \-   3.38    )
                                    Total    1784    144562      146346                                                   
                                                                                                                          
                     *≥ 90 y.o.*    Drug -   194     18898       19092                                                    
                                    Drug +   33      1058        1091        3.04                 (   2.09   \-   4.42    )
                                    Total    227     19956       20183                                                    

###### 

Adjusted ROR for hemorrhagic events

                                              Gastrointestinal hemorrhage   Nerve system hemorrhage                                                                          
  ------------------------------------------- ----------------------------- ------------------------- --- ------- ---- ------- --- --------- ------- --- ------ ---- ------- ---
  Dabigatran                                  \< 0.0001                     7.56                      (   4.92    \-   11.11   )   0.0028    5.61    (   1.99   \-   12.22   )
  Warfarin                                    \< 0.0001                     4.87                      (   4.19    \-   5.64    )   \<.0001   4.83    (   3.55   \-   6.41    )
  Gender male                                 \< 0.0001                     1.42                      (   1.40    \-   1.45    )   \<.0001   1.49    (   1.44   \-   1.55    )
  Reporting year                              \< 0.0001                     0.97                      (   0.96    \-   0.98    )   0.0039    0.98    (   0.97   \-   0.99    )
                                                                                                                                                                             
  ***AGE***                                                                                                                                                                  
  *0-29 y.o.*                                 \< 0.0001                     1.18                      (   1.12    \-   1.23    )   0.4013    1.04    (   0.95   \-   1.14    )
  *30-39 y.o.*                                0.0234                        0.94                      (   0.90    \-   0.99    )   0.0224    0.88    (   0.79   \-   0.98    )
  *40-49 y.o. (as reference)*                 1                                                       1           1                1                 1          1            
  *50-59 y.o.*                                \< 0.0001                     1.16                      (   1.11    \-   1.21    )   0.0005    1.16    (   1.07   \-   1.26    )
  *60-69 y.o.*                                \< 0.0001                     1.45                      (   1.39    \-   1.51    )   \<.0001   1.63    (   1.51   \-   1.77    )
  *70-79 y.o.*                                \< 0.0001                     1.96                      (   1.88    \-   2.04    )   \<.0001   2.27    (   2.09   \-   2.46    )
  *80-89 y.o.*                                \< 0.0001                     2.47                      (   2.36    \-   2.59    )   \<.0001   3.08    (   2.82   \-   3.36    )
  *≥ 90 y.o.*                                 \< 0.0001                     3.02                      (   2.77    \-   3.29    )   \<.0001   2.80    (   2.33   \-   3.33    )
                                                                                                                                                                             
  *interaction term dabigatran \* AGE*                                                                                                                                       
  dabigatran \* *0-29 y.o.*                   0.0021\*                      23.51                     (   12.75   \-   43.34   )   0.1135    16.52   (   4.66   \-   58.53   )
  dabigatran \* *30-39 y.o.*                  0.5924                        8.99                      (   3.89    \-   20.81   )   0.0756    17.79   (   4.63   \-   68.30   )
  dabigatran \* *40-49 y.o. (as reference)*   1                                                       1           1                1                 1          1            
  dabigatran \* *50-59 y.o.*                  0.0862                        12.71                     (   8.20    \-   19.70   )   0.1427    12.41   (   4.86   \-   31.71   )
  dabigatran \* *60-69 y.o.*                  0.0366\*                      16.66                     (   11.01   \-   25.23   )   0.4010    13.20   (   5.35   \-   32.59   )
  dabigatran \* *70-79 y.o.*                  0.0622                        21.45                     (   14.23   \-   32.31   )   0.6436    15.61   (   6.37   \-   38.21   )
  dabigatran \* *80-89 y.o.*                  0.0083\*                      31.36                     (   20.81   \-   47.26   )   0.9646    17.61   (   7.19   \-   43.16   )
  dabigatran \* ≥ *90 y.o.*                   0.0009\*                      45.14                     (   29.30   \-   69.53   )   0.7722    17.98   (   6.98   \-   46.26   )
                                                                                                                                                                             
  *interaction term warfarin \* AGE*                                                                                                                                         
  warfarin \* *0-29 y.o.*                     0.0045\*                      3.71                      (   2.72    \-   5.06    )   0.4350    6.20    (   3.69   \-   10.41   )
  warfarin \**30-39 y.o.*                     0.4767                        4.17                      (   3.18    \-   5.45    )   0.4437    5.19    (   3.15   \-   8.57    )
  warfarin \* *40-49 y.o. (as reference)*     1                                                       1           1                1                 1          1            
  warfarin \* *50-59 y.o.*                    0.8923                        5.59                      (   4.67    \-   6.68    )   0.1804    7.05    (   5.00   \-   9.96    )
  warfarin \* *60-69 y.o.*                    0.5166                        7.45                      (   6.32    \-   8.77    )   0.2650    6.52    (   4.70   \-   9.05    )
  warfarin \* *70-79y.o.*                     0.0019\*                      7.33                      (   6.23    \-   8.62    )   0.0526    7.90    (   5.75   \-   10.87   )
  warfarin \* *80-89 y.o.*                    0.0019\*                      9.21                      (   7.80    \-   10.87   )   0.0640    10.85   (   7.86   \-   14.99   )
  warfarin \* ≥ *90 y.o.*                     0.0002\*                      9.02                      (   6.96    \-   11.69   )   0.3498    10.72   (   6.61   \-   17.40   )

\*Statistically significant
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